A Phase 2, Non-Randomized, Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus mRNA-1647 Vaccine in Participants Who Completed Study mRNA-1647-P202
Latest Information Update: 15 Feb 2024
At a glance
- Drugs MRNA-1647 (Primary)
- Indications Cytomegalovirus infections
- Focus Pharmacodynamics
- Sponsors Moderna Therapeutics
- 08 Feb 2024 Planned End Date changed from 30 Dec 2025 to 30 Dec 2026.
- 08 Feb 2024 Planned primary completion date changed from 30 Dec 2025 to 30 Dec 2026.
- 20 May 2022 Planned number of patients changed from 446 to 291.